FDA Warning Letter To SkinPrint Cites GMP Violations, Unapproved New Acne Drug
Executive Summary
The Skin Atelier, Inc., dba Skinprint, appears to have discontinued sales of OTC drug products on its website, along with Spot-On With 5% Micro-Benz Benzoyl Peroxide Spot Treatment, an unapproved new drug product that the FDA cited in a 1 October warning letter amid a host of GMP violations.